Sanofi increases its stake in Innate Pharma

Sanofi announced that it has crossed the 5% threshold of Innate Pharma's share capital and voting rights. This declaration was made by mail on April 29, 2025. As of April 23, 2025, Sanofi, notably through Sanofi Aventis Participations, acquired 8,345,387 Innate Pharma shares. This represents 9.05% of the share capital and 8.98% of the voting rights.

This move is the result of a subscription to a capital increase at Innate Pharma. Sanofi holds a total of 9.05% of the capital of this company, listed on Euronext Paris. Innate Pharma has a total capital of 92,189,798 shares, corresponding to 92,962,943 voting rights.